Dupixent (dupilumab) is a brand-name injectable drug prescribed for asthma, eczema, and other inflammatory conditions in some adults and children. Dupixent comes in two forms: pens and syringes.

It can affect different areas of your body, including your hands ... are: Dupixent (dupilumab) and Adbry (tralokinumab) are FDA-approved biologic therapies for those with severe eczema that ...

The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s ... the drug came into the hands of Genentech through an acquisition in 2007.

1. Dupixent (dupilumab) for chronic obstructive pulmonary disease: The monoclonal antibody, already approved for eczema, asthma and long-term sinus congestion with nasal polyps, became the first ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.